Kelvin P. Lee is a hematologic oncologist and physician-scientist who has spent more than 25 years studying multiple myeloma, plasma-cell survival and treatment resistance. He began the PIM2 program at Roswell Park and continues it at Indiana University, where he leads NCI-funded work on PIM2, MYC and tumor metabolism. At P2K, he connects disease biology, drug development and the needs of patients with multiple myeloma.
IU profileP2K Dynamics
Our Team
P2K Dynamics brings drug discovery, cancer biology and clinical translation into one integrated team. Together, we are advancing a differentiated therapeutic strategy centered on PIM2 and MYC biology in multiple myeloma.
125+combined years
15+clinical candidates
25+combined years on PIM2/MYC research
Leadership
Select a portrait to read that leader’s biography.Daniela N. Petrusca is a cancer biologist whose work connects cell signaling, cancer metabolism and the bone marrow microenvironment. Over more than 25 years of published research, she has studied cell survival across cancer, immunology and pulmonary vascular biology. At Indiana University, she has investigated GFI1 and sphingolipid signaling in myeloma and coauthored recent PIM2/MYC studies on transcriptional control and mitochondrial function.
IU profileAlmudena Rubio leads medicinal chemistry at P2K Dynamics. Over more than 30 years at Eli Lilly and now P2K, she has designed and advanced small molecules across oncology, neuroscience and metabolic disease. She is a co-inventor of imlunestrant, approved by the FDA in 2025 for advanced breast cancer, and of a KRAS G12D inhibitor now in Phase I. At P2K, she leads chemistry for the non-ATP-competitive PIM2 program.
Chafiq Hamdouchi is a medicinal chemist and drug-discovery leader with experience moving small molecules from target selection through clinical proof of concept. During 23 years at Eli Lilly, he led global teams and contributed to more than ten clinical candidates across oncology and other disease areas. He now co-leads IU’s cancer drug-discovery accelerator. At P2K, he brings chemistry, portfolio judgment and translational planning to the PIM2/MYC program.
IU profileAdvisors
Select a portrait to read that advisor’s biography.Carmen Baldino is a medicinal chemist and biotechnology executive with more than 30 years of experience taking programs from hit identification through IND-enabling work. He has led chemistry and product teams across oncology, neurodegeneration and kidney disease, working with CROs and CDMOs on CMC, toxicology and clinical-supply packages. As president of Jasco Pharmaceuticals, he helped advance aminopyrimidine PIM kinase inhibitors and coauthored early work on JP11646 in multiple myeloma. He advises P2K on medicinal chemistry, lead optimization and the practical choices required to move a small molecule toward the clinic.
IU profileDouglas Balogh is a CMC and regulatory specialist with more than 35 years of experience in pharmaceutical development. At Eli Lilly, he led chemistry, manufacturing and controls work for oncology programs and developed processes for clinical supply and commercial production. As a consultant, he has guided companies through API and formulation development, technology transfer, IND preparation, orphan-drug requests, 505(b)(2) strategies and meetings with the FDA. He advises P2K on how the molecule will be made, tested, documented and supplied consistently as the program moves toward clinical study.
IU profileShripad Bhagwat is an oncology drug-discovery and translational-science leader with more than 25 years of experience in biotech and large pharmaceutical companies. He has led cross-functional programs from portfolio entry to first-in-human studies and delivered eight clinical candidates, including three that reached late-stage development. His work spans cancer biology, preclinical pharmacology, biomarkers, companion diagnostics and early clinical development. A coauthor of the discovery work behind the now FDA-approved imlunestrant, he advises P2K on translational evidence and the decisions that connect laboratory results to clinical testing.
IU profileDavid Calligaro advises P2K on toxicology, nonclinical safety and development risk. He spent nearly 30 years at Eli Lilly, where he led toxicology support for small- and large-molecule programs, built receptor, ion-channel and enzyme selectivity assays, and served as a technical expert in CNS safety pharmacology and drug-abuse liability. His work covered candidate selection, IND-enabling studies, regulatory submissions and interactions with global agencies. Since retiring from Lilly, he has advised biotechnology companies and nonprofit research programs, bringing an experienced safety perspective to decisions from lead selection through early clinical development.
IU profileTim Grese advises P2K on medicinal chemistry, lead generation and portfolio decisions. During more than 30 years in drug discovery, he worked both at the bench and in leadership roles at Eli Lilly, ultimately serving as executive director of lead generation. His teams managed work across more than 100 targets and delivered more than 100 small-molecule leads. Earlier, his research on selective estrogen receptor and other nuclear-receptor modulators contributed to compounds that reached advanced preclinical or clinical evaluation. Since retiring from Lilly, he has advised biotechnology companies, investors and academic drug-discovery groups.
IU profileHenry Havel advises P2K on pharmaceutics, formulation and the transition from lead optimization to IND-enabling development. He brings more than 40 years of experience from Upjohn and Eli Lilly, where he worked across analytical chemistry, oral biopharmaceutics, drug delivery and CMC strategy for small molecules, peptides and proteins. At Lilly, he served as a senior research fellow and helped set technology strategy for small-molecule development. Through Havel BioPharma and IU’s CD3A, he connects physicochemical data, permeability, pharmacokinetics and toxicology to practical formulation choices and clinical exposure goals.
IU profileMichael Martinelli is a pharmaceutical development executive with experience moving small molecules from candidate selection through clinical development and commercial supply. He currently serves as a vice president at Exelixis and advises IU’s Cancer Drug Discovery and Development Accelerator. At FibroGen, he led CMC development for clinical candidates including roxadustat during its Phase 2b program; earlier roles at Eli Lilly and Amgen covered medicinal chemistry, process development and complex heterocycle synthesis. He brings P2K practical judgment in CMC strategy, scale-up, supply planning, IND-enabling work and the transition from lead compound to clinic.
IU profileAdrienne Takacs is an advisor to IU’s CD3A and Indiana CTSI drug-development programs. Across more than 30 years in biopharma, she has led drug metabolism and pharmacokinetics, R&D operations, regulatory planning and strategic alliances. At Eli Lilly, she oversaw preclinical DMPK support for more than 10 oncology programs, managed global scientific teams and helped prepare IND and NDA submissions; she also held drug-metabolism leadership at Johnson & Johnson. She advises P2K on evidence, risk and the decisions that move programs from lead optimization through clinical development.
IU profileJim Wikel is a medicinal and computational chemist with more than five decades in drug discovery. At Eli Lilly, he worked as a laboratory scientist and research leader, ultimately heading structural and computational sciences and helping establish predictive methods for medicinal chemistry. His publications and patents cover antiviral, immunosuppressive, oncology and agricultural compounds, including molecules that reached clinical evaluation. He later helped develop APE1/Ref-1 inhibitors through Apexian Pharmaceuticals and Indiana University collaborations. He advises P2K on hit finding, lead optimization, in silico modeling and candidate selection through IND-enabling development.
IU profile